[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zomagen Biosciences Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100580356",false,"NCT06836232","An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis","A Phase 2a, Open-Label Pilot Study to Evaluate the Safety\u002FTolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants With Recurrent Pericarditis","Inclusion Criteria:\n\n* Participants are male or female ≥ 18 years up to ≤ 75 years of age.\n* Capable of giving signed informed consent and able to comply with the protocol\n* Previously had an index (first) episode of pericarditis which met the criteria for an acute pericarditis event\n* Ongoing symptomatic episode of pericarditis, or may have an episode of recurrent pericarditis in the next 4 weeks.\n* CRP by local laboratory assessment prior to first dose of study treatment (participants with CRP ≤ 10 mg\u002FL must be receiving corticosteroid treatment for RP and have evidence of pericardial inflammation)\n* Pericarditis pain score ≥ 4 based on the 11-point NRS.\n* Stable doses of NSAIDs, colchicine, and\u002For oral corticosteroids (if receiving these treatments)\n\nExclusion Criteria:\n\n* Current or prior diagnosis of pericarditis that is secondary to specific prohibited causes, including but not limited to tuberculosis, blunt trauma, tumor, myocarditis, or systemic autoimmune diseases.\n* History of clinically significant immunosuppressive disorder, autoimmune\u002Fautoinflammatory disorder, or primary or secondary immunodeficiency.\n* Clinically important history of a medical disorder that would compromise safety or data quality, per the Investigator's judgment.","ALL","18 Years","75 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP).\n\nCohort A will include approximately 10 participants and will consist of the following:\n\n* A 30-day Screening Period (to see if a participant qualifies for the study)\n* A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A\n* A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A\n* An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B\n* A 14-day Follow-Up Period\n\nCohort B will include approximately 20 participants and will consist of the following:\n\n* A 30-day Screening Period (to see if a participant qualifies for the study)\n* A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C\n* An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C\n* A 14-day Follow-Up Period\n\nCohort C will include approximately 20 participants and will consist of the following:\n\n* A 30-day Screening Period (to see if a participant qualifies for the study)\n* A 6-week Open Label Treatment Period - participant receives VTX2735 Dose D or E, and B\n* An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B\n* A 14-day Follow-Up Period",[26],"Recurrent Pericarditis",[28,29,26,30,31,32,33],"Ventyx","Zomagen","VTX2735","NLRP3 Inhibitor","NLRP3","Inflammasome","RECRUITING","2026-05-20",{"date":37,"type":38},"2026-05-22","ACTUAL",{"date":40,"type":38},"2025-01-28",{"date":42,"type":20},"2027-10",{"name":44,"class":45},"Zomagen Biosciences Ltd.","INDUSTRY",18,""]